author-photo

Steve Bender

Pfizer

14

Papers

1435

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

RECOGNIZING, DIAGNOSING, AND TREATING TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM): TARGETING CONTINUING MEDICAL EDUCATION (CME) TO THOSE WHO AREN’T TREATING ATTR-CM

2021 Journal of the American College of Cardiology
Show All
- Source
- Cite
- Save
Citations (0)
Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation

2013 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (29)
Structure Based Drug Design of Crizotinib (Pf-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (C-met) Kinase and Anaplastic Lymphoma Kinase (Alk).

2011 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (628)
Abstract LB-390: Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor, in EML4-ALK driven NSCLC tumors in vitro and in vivo

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (4)
Abstract 5409: Ron silencing by shRNA inhibits growth, induces apoptosis and sensitizes tumor response to c-Met inhibitor treatment through down-regulating MAPK signaling in B-Raf mutant colon carcinomas

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

2010 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (59)
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy

2008 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (13)
Prinomastat: A Potent and Selective Matrix Metalloprotease Inhibitor–Preclinical and Clinical Development for Oncology

2000
Show All
- Source
- Cite
- Save
Citations (8)
Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials.

1999 Annals of the New York Academy of Sciences
Show All
- Source
- Cite
- Save
Citations (218)